Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Haemonetics (HAE) over the last 17 years, with Q4 2025 value amounting to $87.2 million.

  • Haemonetics' Free Cash Flow rose 14762.92% to $87.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $308.1 million, marking a year-over-year increase of 21141.02%. This contributed to the annual value of $142.4 million for FY2025, which is 82.09% down from last year.
  • Haemonetics' Free Cash Flow amounted to $87.2 million in Q4 2025, which was up 14762.92% from $106.3 million recorded in Q3 2025.
  • In the past 5 years, Haemonetics' Free Cash Flow registered a high of $106.3 million during Q3 2025, and its lowest value of -$33.1 million during Q2 2024.
  • Its 5-year average for Free Cash Flow is $32.0 million, with a median of $34.1 million in 2022.
  • Its Free Cash Flow has fluctuated over the past 5 years, first plummeted by 47898.45% in 2021, then skyrocketed by 52692.65% in 2024.
  • Haemonetics' Free Cash Flow (Quarter) stood at $22.6 million in 2021, then soared by 110.03% to $47.6 million in 2022, then crashed by 131.93% to -$15.2 million in 2023, then skyrocketed by 331.92% to $35.2 million in 2024, then soared by 147.63% to $87.2 million in 2025.
  • Its Free Cash Flow was $87.2 million in Q4 2025, compared to $106.3 million in Q3 2025 and $13.6 million in Q2 2025.